Oral neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Oral neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Nivolumab for Patients with Oral Cancer to Reduce Tumor Size Before Surgery https://clinicaltrials.eu/trial/study-of-nivolumab-for-patients-with-oral-cancer-to-reduce-tumor-size-before-surgery/ Wed, 29 Apr 2026 15:04:59 +0000 https://clinicaltrials.eu/trial/study-of-nivolumab-for-patients-with-oral-cancer-to-reduce-tumor-size-before-surgery/ This clinical trial is focused on studying Oral Squamous Cell Carcinoma (OSCC), a type of cancer that affects the mouth. The treatment being tested is called Nivolumab, also known by its code names BMS936558 and ABP 206. Nivolumab is a medication that is given as an infusion, which means it is delivered directly into the bloodstream through a vein. The purpose of the study is to see how effective Nivolumab is in reducing the size of the primary tumor before surgery.

Participants in the study will receive two doses of Nivolumab before their planned surgery. The study will monitor how the tumor responds to the treatment and whether it becomes smaller. Researchers will also look at the lymph nodes, which are small glands that help fight infection, to see if they can predict how well the treatment is working. The study will also track any side effects that participants may experience from the treatment.

The trial will continue to follow participants for up to five years to observe their overall health and survival rates. This long-term follow-up will help researchers understand the full impact of Nivolumab on the disease and its potential benefits for patients with Oral Squamous Cell Carcinoma. The study aims to provide valuable information that could improve treatment options for this type of cancer in the future.

]]> Study on Electrochemotherapy with Bleomycin for Patients with Recurrent Oral and Oropharyngeal Cancer https://clinicaltrials.eu/trial/study-on-electrochemotherapy-with-bleomycin-for-patients-with-recurrent-oral-and-oropharyngeal-cancer/ Wed, 29 Apr 2026 15:04:07 +0000 https://clinicaltrials.eu/trial/study-on-electrochemotherapy-with-bleomycin-for-patients-with-recurrent-oral-and-oropharyngeal-cancer/ This clinical trial is focused on studying a treatment for squamous cell carcinoma of the oral cavity and oropharynx, which are areas in the mouth and throat. The study is investigating the effectiveness of a treatment called electrochemotherapy, which combines the use of electrical impulses with a drug called bleomycin. This treatment will be compared to a combination of other medications, including cetuximab, platinum-based therapy (such as carboplatin or cisplatin), and 5-fluorouracil.

The purpose of the study is to determine if electrochemotherapy with bleomycin is more effective in treating the cancer compared to the other combination of drugs. Participants in the study will receive either the electrochemotherapy treatment or the combination of cetuximab, platinum-based therapy, and 5-fluorouracil. The study will monitor the response of the cancer to these treatments, as well as overall survival, the time the disease remains under control, and the quality of life of the participants.

Throughout the study, participants will receive their assigned treatment and be regularly assessed to track the progress of their cancer and any side effects they may experience. The study aims to provide valuable information on the best treatment options for patients with recurrent squamous cell carcinoma of the oral cavity and oropharynx.

]]> Study on Improving Oral Cancer Surgery Using cRGD-ZW800-1 Fluorescent Imaging for Patients with Oral Cancer https://clinicaltrials.eu/trial/study-on-improving-oral-cancer-surgery-using-crgd-zw800-1-fluorescent-imaging-for-patients-with-oral-cancer/ Wed, 29 Apr 2026 15:03:13 +0000 https://clinicaltrials.eu/trial/study-on-improving-oral-cancer-surgery-using-crgd-zw800-1-fluorescent-imaging-for-patients-with-oral-cancer/ This clinical trial focuses on improving the surgical removal of oral cancer using a special technique called fluorescence imaging. Oral cancer refers to cancer that occurs in the mouth, and the goal of this study is to make sure that the cancer is removed more completely during surgery. The treatment being tested is a new medication called cRGD-ZW800-1, which is given through an intravenous infusion. This medication helps doctors see the cancer more clearly during surgery by making it glow under a special light.

The purpose of the study is to find the best dose of cRGD-ZW800-1 that will make the cancer stand out the most from the surrounding healthy tissue. This will help surgeons remove the cancer with a clear margin, meaning they take out a small amount of healthy tissue around the cancer to ensure all cancer cells are removed. The study will also look at how well this technique works in identifying cancer that has spread to nearby lymph nodes.

Participants in the study will receive the cRGD-ZW800-1 medication before their surgery. During the operation, the surgeon will use the fluorescence imaging technique to guide the removal of the cancer. The study will monitor how well the cancer is removed and how much extra tissue is taken out based on the imaging. The study aims to improve the success of oral cancer surgeries and reduce the chances of cancer coming back.

]]>